Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Microba Life Sciences Limited ( (AU:MAP) ).
Microba Life Sciences Limited has announced the quotation of 67,177,796 fully paid ordinary securities on the Australian Securities Exchange (ASX) under the code MAP. This move is part of previously announced transactions and is expected to enhance the company’s market presence and liquidity, potentially benefiting stakeholders by increasing the accessibility of its shares.
The most recent analyst rating on (AU:MAP) stock is a Buy with a A$0.33 price target. To see the full list of analyst forecasts on Microba Life Sciences Limited stock, see the AU:MAP Stock Forecast page.
More about Microba Life Sciences Limited
Microba Life Sciences Limited operates in the biotechnology industry, focusing on microbiome analysis and related health services. The company is known for its advanced microbiome testing and analysis products, which are utilized in both healthcare and research settings.
Average Trading Volume: 202,977
Technical Sentiment Signal: Sell
Current Market Cap: A$38.52M
For detailed information about MAP stock, go to TipRanks’ Stock Analysis page.